RAP-219 Heads Into Phase 3 for Focal Onset Seizures as FDA Green-Lights Trial Launch

Rapport Therapeutics (RAPP) received FDA authorization to move RAP-219 directly into registrational studies, enabling the company to launch its Phase 3 program targeting focal onset seizures in Q2 2026. This clearance reflects compelling Phase 2a trial results and marks RAP-219 as a potential category-leading treatment option within the epilepsy landscape.

The Clinical Opportunity

Focal onset seizures represent one of the most prevalent epilepsy presentations, characterized by recurring breakthrough episodes in patients. Existing treatment options frequently struggle with side effect burdens and incomplete seizure suppression, creating substantial therapeutic gaps. RAP-219 functions as a targeted molecular therapy, engineered to modulate specific brain receptor pathways with the goal of enhancing seizure control and patient outcomes.

Phase 3 Trial Design and Timeline

The registrational trial will operate as a multicenter, randomized, placebo-controlled study in adult patients experiencing focal onset seizures. Study participants will be randomized to receive either RAP-219 or placebo, with primary metrics assessing reductions in monthly seizure events alongside long-term safety monitoring. Concurrently, Rapport initiated a continued-access arm allowing Phase 2a participants to resume treatment; preliminary results from this extension study should emerge during the latter half of 2026.

Expanding the Epilepsy Pipeline

Beyond focal onset seizures, Rapport is advancing development into primary generalized tonic-colonic seizures (PGTCS), the predominant generalized seizure subtype. A Phase 3 program in PGTCS is anticipated to initiate in H1 2027. The company is simultaneously progressing a Phase 2 evaluation in bipolar mania, while developing an extended-release injectable variant and pursuing additional clinical programs in neuropathic pain, migraine prophylaxis, and sensorineural hearing conditions.

Financial Position and Stock Performance

Rapport maintained a balance sheet of $531 million in cash and short-term investments at quarter-end, positioning the company to sustain operations through H2 2029. Over the trailing twelve months, RAPP shares have traded within a $5.66 to $42.39 range. In the prior session, the stock closed at $32.42, representing a 5.16% gain, and extended gains in after-hours trading to reach $32.90, up an additional 1.48%.